{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:16:16Z","timestamp":1792224976665,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ejca.2023.03.011","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T12:16:53Z","timestamp":1679055413000},"page":"166-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Has the advent of modern adjuvant systemic therapy for melanoma rendered sentinel node biopsy unnecessary?"],"prefix":"10.1016","volume":"186","author":[{"given":"Alexander H.R.","family":"Varey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Howle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serigne N.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Ch\u2019ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.03.011_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.annonc.2020.11.015","article-title":"Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor","volume":"32","author":"El Sharouni","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.03.011_bib2","first-page":"835","article-title":"Therapeutic value of sentinel lymph node biopsy in patients with melanoma: a randomized clinical trial","volume":"157","author":"Crystal","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ejca.2023.03.011_bib3","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA: Cancer J\u00a0Clin"},{"key":"10.1016\/j.ejca.2023.03.011_bib4","unstructured":"(NCCN) NCCN. Melanoma: Cutaneous NCCN Clinical Practice Guidelines in Oncology. 2.2021 ed.\u00a02021."},{"key":"10.1016\/j.ejca.2023.03.011_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5694\/mja17.00278","article-title":"Updated evidence-based clinical practice guidelines for the diagnosis and management of melanoma: definitive excision margins for primary cutaneous melanoma","volume":"208","author":"Sladden","year":"2018","journal-title":"Med J Aust"},{"key":"10.1016\/j.ejca.2023.03.011_bib6","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.03.011_bib7","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.03.011_bib8","article-title":"Sentinel node biopsy for melanoma: unnecessary treatment?","volume":"346","author":"Torjesen","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2023.03.011_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2017.06.006","article-title":"Adjuvant interferon-alpha for the treatment of high-risk melanoma: an individual patient data meta-analysis","volume":"82","author":"Ives","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.03.011_bib10","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.03.011_bib11","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.03.011_bib12","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB\u2013C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.03.011_bib13","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(22)00559-9","article-title":"Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: the phase 3 KEYNOTE-716 study","volume":"23","author":"Long","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.03.011_bib14","unstructured":"Bristol-Myers Squibb, Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma. 2022."},{"key":"10.1016\/j.ejca.2023.03.011_bib15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/01.sla.0000181092.50141.fa","article-title":"Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial","volume":"242","author":"Morton","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2023.03.011_bib16","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.bjps.2011.05.001","article-title":"Sentinel lymph node biopsy in melanoma: The Oxford ten year clinical experience","volume":"64","author":"Rughani","year":"2011","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"10.1016\/j.ejca.2023.03.011_bib17","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1245\/s10434-019-07375-y","article-title":"Negative sentinel lymph node biopsy in patients with melanoma: the patient's perspective","volume":"26","author":"Banting","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2023.03.011_bib18","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1245\/s10434-020-08558-8","article-title":"Sentinel lymph node biopsy for T1b melanoma: balancing prognostic value and cost","volume":"27","author":"Hu","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2023.03.011_bib19","first-page":"835","article-title":"Therapeutic value of sentinel lymph node biopsy in patients with melanoma: a randomized clinical trial","volume":"157","author":"Multicenter Selective Lymphadenectomy Trials Study","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ejca.2023.03.011_bib20","first-page":"182","article-title":"Long-term safety of pembrolizumab monotherapyand relationship with clinical outcome:\u00a0a\u00a0landmarkanalysis in patients with advanced melanoma","volume":"144","author":"Robert","year":"2021","journal-title":"Eur\u00a0J\u00a0Cancer"},{"key":"10.1016\/j.ejca.2023.03.011_bib21","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2023.03.011_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100303","article-title":"Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation","volume":"6","author":"Mulder","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2023.03.011_bib23","first-page":"599","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N\u00a0Engl\u00a0J\u00a0Med"},{"key":"10.1016\/j.ejca.2023.03.011_bib24","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1245\/s10434-010-1203-0","article-title":"The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I)","volume":"17","author":"Faries","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2023.03.011_bib25","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.03.011_bib26","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1200\/JCO.2010.30.9567","article-title":"Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes","volume":"28","author":"Murali","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.03.011_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jamcollsurg.2016.01.045","article-title":"Impact of completion lymph node dissection on patients with positive sentinel lymph node biopsy in melanoma","volume":"223","author":"Lee","year":"2016","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ejca.2023.03.011_bib28","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1245\/s10434-021-09804-3","article-title":"Nodal recurrence is a primary driver of early relapse for patients with sentinel lymph node-positive melanoma in the modern therapeutic era","volume":"28","author":"Mitra","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.03.011_bib29","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/bjs.11621","article-title":"Nodal and systemic recurrence following observation of a positive sentinel lymph node in melanoma","volume":"107","author":"Bartlett","year":"2020","journal-title":"Br J Surg"},{"issue":"32","key":"10.1016\/j.ejca.2023.03.011_bib30","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.22.00202","article-title":"Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer Version 8 validated in two independent cohorts: implications for adjuvant treatment","volume":"40","author":"Garbe","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10366","key":"10.1016\/j.ejca.2023.03.011_bib31","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"The Lancet"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:34Z","timestamp":1760733634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923001478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":31,"alternative-id":["S0959804923001478"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.03.011","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Has the advent of modern adjuvant systemic therapy for melanoma rendered sentinel node biopsy unnecessary?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}